VEGFA and Abnormal retinal morphology: Ranibizumab, a humanized anti-VEGF-A Ab fragment, and brolucizumab, a single-chain anti-VEGF-A Ab, continue to improve retinal disease outcomes.661,662 The NORSE-EIGHT clinical trial validated ranibizumab’s superior efficacy over bevacizumab in improving best-corrected visual acuity.663 Notably, bevacizumab, under the brand name LYTENAVATM, has received regulatory approval for wet AMD treatment in the EU and UK.664